CTLA-4, present on the surface of cluster differentiation (CD) 4+ and CD8+ lymphocytes, is another important pharmacological target for the treatment of several neoplastic forms, including metastatic melanoma [49]. This evidence concerns the gene CTLA4 and metastatic melanoma.